[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain-nervous-system-cancers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain-nervous-system-cancers":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,57,93,127,152,174,198,229,257,282],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100638098","pire-20-a-stepped-care-model-for-involving-relatives-across-sectors-100638098",false,"NCT07590726","PIRe 2.0: A Stepped-Care Model for Involving Relatives Across Sectors","PIRe","Inclusion Criteria\n\n* Primary relative of an adult diagnosed with acquired brain injury (ABI) or malignant brain tumor (MBT), admitted to a participating hospital department.\n* Formally identified as the primary relative by the patient.\n* Aged ≥18 years.\n* Ability to read, understand, and complete questionnaires in Danish.\n\nExclusion Criteria\n\n* Insufficient proficiency in Danish to complete questionnaires and participate in structured conversations.\n* Concurrent participation in another interventional study with a similar aim that may interfere with the present study.","ALL","18 Years",{"count":19,"type":20},160,"ESTIMATED","INTERVENTIONAL",[23],"NA","Serious brain diseases and injuries affect not only the person who becomes ill or injured, but also their family. Relatives of people with acquired brain injury (ABI) or malignant brain tumor (MBT) often take on a major role in daily care, decision-making, and coordination across healthcare services. This role can include managing information, supporting rehabilitation, and acting as a link between hospital care and community rehabilitation. Many relatives report high levels of stress, uncertainty, and emotional burden, especially during transitions between care settings.\n\nDespite recommendations for greater involvement of relatives, support for this group is often uneven and poorly coordinated across healthcare sectors. Relatives frequently experience lack of overview, limited guidance, and unclear expectations regarding their role. These challenges may increase caregiver burden and negatively affect both relatives' well-being and the continuity of care.\n\nThe PIRe 2.0 study aims to further test, and implement a structured intervention to support systematic involvement of relatives of people with ABI or MBT across hospital and community rehabilitation services. The intervention is designed as a \"caregiver compass\" that helps relatives understand their role, clarify their needs and wishes for involvement, and gain better overview of the care pathway.\n\nPIRe 2.0 is delivered through a stepped-care model, which allows the level of support to be adjusted over time based on each relative's level of burden and support needs. All relatives receive basic information and screening for caregiver burden using the 4-item Zarit Burden Interview (ZBI-4). Relatives who show signs of increased burden are offered additional support in steps, ranging from structured conversations with nurses to extended cross-sector coordination and specialized support for relatives with high or complex needs. Decisions about stepping up or down are based on both screening results and clinical assessment to ensure flexibility and person-centered care.\n\nThe study includes two groups of relatives: an intervention group receiving support through the PIRe stepped-care model, and a control group receiving usual care only. A total of 160 relatives will participate. Data are collected at baseline, at transitions between hospital and community care, and three to six months after the intervention.\n\nThe primary outcome is change in caregiver burden, measured with the Caregiver Burden Scale (CBS). Secondary outcomes include relatives' roles and responsibilities, perceived support and involvement in care, and mental well-being, assessed using validated patient-reported outcome measures.\n\nIn addition to evaluating the effect of the intervention, the study examines how the PIRe model can be implemented and sustained in everyday practice across healthcare sectors. The results are expected to show whether a structured, stepped-care approach can reduce caregiver burden, improve coordination between hospital and community services, and support more coherent and secure care pathways for people with ABI or malignant brain tumor and their relatives.",[26,27,28,29,30,31,32],"Brain Injuries, Acute","Brain Tumor Adult","Brain (Nervous System) Cancers","Traumatic Brain Injuries","Glioblastom WHO Grade 4","Glioblastoma (GBM)","Stroke",[34,35,36,37,38,39,40,41,42,43],"Acquired brain injury","Malignant brain tumor","Relatives","Caregiver Burden","Involvement","Communication","Care transitions","Rehabilitation","Implementation","Stepped-care","NOT_YET_RECRUITING","2026-05-15",{"date":47,"type":48},"2026-05-19","ACTUAL",{"date":50,"type":20},"2026-10-01",{"date":52,"type":20},"2029-09-30",{"name":54,"class":55},"Rigshospitalet, Denmark","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":69,"conditions":70,"keywords":81,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":56},"100621015","mrinrt-swansea-university-and-swwcc-collaboration-study-100621015","NCT07365124","MRinRT: Swansea University and SWWCC Collaboration Study.","Developing and Optimising the Use of Magnetic Resonance Imaging and Spectroscopy in Radiotherapy (MRinRT) Pathways: Investigating Avenues to Improve Outcomes for Patients and the Assessment of Treatment Response.","MRinRT","Inclusion Criteria for health volunteers:\n\n* Free from medical conditions that could confound imaging or study results\n* Eligible for MRI\n\nInclusion Criteria for patients:\n\n* Confirmed diagnosis of invasive carcinoma at the relevant tumour\u002Ftarget sites listed in this protocol\n* Scheduled to receive radiotherapy to the target site\n* ECOG performance status of 0-2\n* Eligible for MRI (determined through MRI safety screening)\n\nExclusion Criteria:\n\n* Presence of medical conditions that may interfere with study outcomes or data interpretation\n* Use of regular medications that could affect imaging results or safety\n* Any contraindications to MRI scanning, including but not limited to claustrophobia, reduced thermal regulatory capabilities, MR Unsafe implants and foreign bodies.",true,{"count":67,"type":20},165,"OBSERVATIONAL","The aim of this study is to learn whether using MRI (magnetic resonance imaging) scans to plan radiotherapy is better than using CT (computed tomography) scans alone. The main questions it aims to answer is:\n\n* Can MRI scan images be adjusted to make the tumour and normal tissues easier to see?\n* Does adding MRI to a radiotherapy planning CT make the radiotherapy plan more precise?\n* Can MRI be used to adjust a radiotherapy plan during a course of treatment to make it more precise, and might that reduce the side effects?\n* Are there particular MRI scans that can predict how a tumour will respond to radiotherapy or how likely the patient is to have side effects?\n\nThis study will assess current MRI scanning procedures and ensure these are adjusted to best suit radiotherapy planning. It will also provide pilot data evaluating:\n\n1. MRI-adapted radiotherapy Usually, radiotherapy plans are based on a pre-treatment planning CT scan. Unless an issue is detected the patient would complete their whole course of radiotherapy on this plan. This does not account for changes in position\u002Fsize\u002Fshape of the tumour that occur over the whole treatment course. Clinicians therefore increase the size of the tumour\u002Ftarget to account for these uncertainties, which can increase side effects. This study will assess the potential to reduce side effects from radiotherapy by using repeat MRI scans and replanning during the treatment course (MRI-adaptive radiotherapy).\n2. Imaging biomarkers MRI sequences can be used to predict response to radiotherapy or chance of developing side effects. This study will identify potential MRI sequences that may be used as imaging biomarkers, to guide the development of future clinical trials.\n\nThe study will be undertaken at SBUHB, lasting 4 years, and involving ≤15 healthy volunteers and ≤150 patients.",[71,72,73,74,75,76,77,78,79,80,28],"Carcinoma","Glioblastoma","Radiotherapy","MRI","MRI-guided Adaptive Radiotherapy","MRI Scanner Configuration","MRI Image Enhancement","Oesophageal Carcinoma","Pancreas Carcinoma","Gastric Cancer",[74,73,82,83],"MRI adaptive radiotherapy","MRI Imaging Biomarker","2026-04-29",{"date":86,"type":48},"2026-04-30",{"date":88,"type":20},"2026-05",{"date":90,"type":20},"2032-01",{"name":92,"class":55},"Swansea Bay University Health Board",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":104,"conditions":105,"keywords":112,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":126},"100577927","phase-2-pharmacoscopy-for-patients-with-refractory-primary-brain-tumors-100577927","NCT06804655","Pharmacoscopy for Patients With Refractory Primary Brain Tumors","EViDENCE-BT","Inclusion Criteria:\n\n1. Age 18 years or older on day of signing informed consent, female or male.\n2. Refractory glioblastoma, isocitrate dehydrogenase (IDH)-mutant astrocytoma or oligodendroglioma, histone-mutant glioma, ependymoma, medulloblastoma, meningioma or other rare primary brain tumor with a histological confirmation according to the WHO classification 2021. Primary tumors can be located at the cerebral or spinal level. Primary brain tumors with metastases outside of the brain may also be considered.\n3. Karnofsky performance status of 60 or more\n4. Life expectancy \\>12 weeks.\n5. Limited systemic therapeutic options as per treating physician judgement. The number of previous lines of therapies is not limited.\n6. Surgery clinically indicated. A histological confirmation of the diagnosis of a recurrent brain tumor will be required before any treatment can be initiated.\n7. Adequate bone marrow, renal and hepatic function\n8. Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments.\n9. Written informed consent for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.\n\nExclusion Criteria:\n\n1. Inability to undergo brain or spine MRI.\n2. Concurrent treatment with other systemic tumor-directed pharmacotherapies.\n3. Intent to be treated with radiotherapy.\n4. Any investigational antitumor therapy other than those under investigation in this study.\n5. Judgment by the investigator that the patient should not participate in the study because the patient is unlikely to comply with study procedures, restrictions and requirements.\n6. Intention to become pregnant during the course of the study or pregnancy. Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test.\n7. Women who are breast feeding and who do not agree to discontinue nursing prior to the first study treatment and for the period defined in the protocol.\n8. Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study.",{"count":101,"type":20},40,[103],"PHASE2","Advanced technology of ex vivo drug profiling referred to as pharmacoscopy may allow to identify novel drugs for the treatment of glioblastoma and other refractory brain tumors at an individual patient level. This personalized therapeutic approach was developed and validated in pre-clinical glioma models. With the current research proposal, we seek to establish feasibility for a clinical interventional trial for patients with refractory primary brain tumors that is based on pharmacoscopy-guided selection of treatment.\n\nThe study is supported by an unrestricted grant from Anti Cancer Fund.",[28,72,106,107,108,109,110,111],"Glioma","Ependymoma","Medulloblastoma","Meningioma","Rare Primary Brain Tumors","Rare CNS Primary Tumors",[113,114,115,116,117],"pharmacoscopy","drug testing","refractory tumor","drug repurposing","personalized medicine",{"date":119,"type":48},"2026-05-06",{"date":121,"type":20},"2026-06-01",{"date":123,"type":20},"2028-09-15",{"name":125,"class":55},"University of Zurich",3,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":21,"phases":137,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":4},"100631084","phase-1-a-phase-i-single-arm-open-label-clinical-study-to-evaluate-the-safety-pharmacokinetics-and-preliminary-efficacy-of-cht101-cell-infusion-in-adult-subjects-with-recurrent-or-progressive-malignant-primary-brain-tumorscrown-100631084","NCT07496073","A Phase I, Single-arm, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Cell Infusion in Adult Subjects With Recurrent or Progressive Malignant Primary Brain Tumors（CROWN）","A Phase I, Single-arm, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Cell Infusion in Adult Subjects With Recurrent or Progressive Malignant Primary Brain Tumors","Inclusion Criteria:\n\n* Tumor tissue specimens must be CD70-positive as determined by immunohistochemistry (IHC).\n\nSubjects must be pathologically confirmed to have high-grade glioma, defined as WHO (2021) Central Nervous System Tumor Classification grade 3 or 4 gliomas; or primary central nervous system lymphoma (PCNSL).\n\nContrast-enhanced magnetic resonance imaging (MRI) must demonstrate the presence of an intracranial space-occupying lesion, with at least one measurable lesion.\n\nAt the time of signing the informed consent form (ICF), the Karnofsky Performance Status (KPS) score must be ≥70.\n\nExclusion Criteria:\n\n* Patients with brainstem recurrence, spinal dissemination, or extracranial metastasis.\n\nHistory of bone marrow or solid organ transplantation. History of other primary malignancies within 5 years prior to study treatment. Prior receipt of CD70-targeted antitumor therapies, including but not limited to CD70-targeted cell therapies (autologous or allogeneic) and TCR-T therapy.\n\nPrior treatment with CAR-T therapy or other cell\u002Fgene therapies. Presence of acute or moderate-to-severe chronic graft-versus-host disease (GVHD) within 4 weeks prior to signing the informed consent form (ICF), or receipt of systemic therapy for GVHD within 4 weeks prior to the first infusion.\n\nClinically significant cardiovascular disease. Epilepsy that is difficult to control with medication, or chronic symptoms and signs of intracranial hypertension.\n\nInadequate bone marrow reserve or organ function. Pregnant or breastfeeding female subjects.","70 Years",{"count":136,"type":20},30,[138],"PHASE1","Recurrent or progressive primary malignant brain tumors are among the malignancies with a poor prognosis. They refer to primary brain tumors that either recur after standard treatment or show disease progression during the course of standard therapy. This group includes a variety of histological types, most commonly glioblastoma, anaplastic astrocytoma, anaplastic oligodendroglioma, and primary central nervous system lymphoma.",[28],[142],"Primary Malignant Brain Tumors","2026-03-22",{"date":145,"type":48},"2026-03-27",{"date":147,"type":20},"2026-03-20",{"date":149,"type":20},"2028-03-31",{"name":151,"class":55},"Tianjin Medical University Cancer Institute and Hospital",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":65,"sex":16,"minAge":17,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":56},"100505307","clinical-pathological-and-imaging-project-of-neuro-oncology-hope-100505307","NCT05859659","Clinical, patHOlogical and Imaging Project of nEuro-oncology (HOPE)","Inclusion Criteria:\n\n* (1) a clear diagnosis of glioma based on pathological results;\n* (2) The MRI sequence is complete and there are no obvious artifacts in the image;\n* (3) The patient signs an informed consent form\n\nExclusion Criteria:\n\n* (1) Suffering from other neurological diseases;\n* (2) Prior to enrollment, surgery or biopsy, or a history of radiation therapy or chemotherapy;\n* (3) Unable to complete clinical scoring and related laboratory tests, unable to complete follow-up;\n* (4) Unable to tolerate MRI examination; Poor image quality, such as motion artifacts.","90 Years",{"count":160,"type":20},70000,"Primary central nervous system (CNS) tumors, the vast majority (\\>90%) occurring in the brain and the remainder occurring in the meninges, spinal cord, and cranial nerves, showing an annual incidence of about 6-8 people per 100,000 population but its effects on health-care systems is out of proportion with incidence due to the substantial high rates of morbidity and mortality. Among which, glioma disease is the most common primary malignant CNS tumor, while the glioblastoma that showed the highest degree of malignancy and the worst prognosis accounts for 70-75%.\n\nThe construction goal of this project is to construct a multivariate retrospective CNS tumor database (over 50,000 cases, including 10,000 glioma) integrating clinical information, preoperative magnetic resonance imaging examination and molecular pathological results, and a prospective glioma database (3,000 cases) integrating advanced magnetic resonance sequences and postoperative follow-up. It aims to form a standardized database integrating magnetic resonance imaging, pathological results, and clinical-prognostic information.\n\nBased on the construction of the above standardized database, the specifications for the acquisition of cranial magnetic resonance images, the image segmentation, tumor classification and labeling process, and the expert consensus on database construction and use management of CNS tumors were established. We aim to form a multimodal, large-capacity, high-quality, and rich medical imaging database that conforms to the characteristics of Chinese groups and clinical diagnosis and treatment norms. On this basis, the data are dynamically updated, in-depth mining, and the classification and grading standards of CNS tumor diseases, prognosis judgment criteria and treatment efficacy evaluation system are formulated, and providing comprehensive resources of retrospective data and prospective cohorts for large-scale reasearches, such as classification or treatment intervention predictions.",[28,106,163],"Brain Tumor","RECRUITING","2026-03-05",{"date":167,"type":48},"2026-03-09",{"date":169,"type":48},"2022-01-01",{"date":171,"type":20},"2030-12-31",{"name":173,"class":55},"Yaou Liu",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":21,"phases":184,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":56},"100605417","phase-2-combined-gamma-knifelinac-radiosurgery-for-large-brain-tumors--metastases-100605417","NCT07162246","Combined Gamma Knife\u002FLinac Radiosurgery for Large Brain Tumors \u002F Metastases","Combined Gamma Knife\u002FLinac Hypofractionated Stereotactic Radiosurgery for Large Intracranial VolumEs (GK-LIVE): A Prospective Phase II Single-Arm Trial","GK-LIVE","Inclusion Criteria:\n\n* Presence of up to two large intracranial lesions\n* Up to 10 (previously untreated, or progressing after previous treatment) brain metastases at the time of enrollment on the diagnostic MRI (which includes the ILLs) to be treated with SRS\u002FHSRS\n* Age =\\> 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Expected survival \\>3 months\n* Patients that are deemed suitable for both GK and Linac based treatment\n* Patients that are able to hold systemic cancer chemotherapy\u002Fimmunotherapy at least 2 days prior and following an SRS fraction\n\nExclusion Criteria:\n\n* Prior SRS to the ILLs\n* Prior WBRT, or plan for concurrent WBRT with the protocol treatment\n* Presence or history of any leptomeningeal\u002Fpachymeningeal disease\n* Metastatic disease within the ventricles of the brain or corpus callosum\n* Small cell, hematopoietic or germ cell primaries\n* Patient with absolutely contraindications for MRI\n* Severe symptoms that preclude MRI or treatment using standard procedures for Linac or GK\n* Pregnant or lactating patient\n* Inability or unwillingness to undergo informed consent or post-treatment follow-up",{"count":183,"type":20},60,[103],"When cancer spreads to the brain, doctors often use a precise type of radiation therapy called stereotactic radiosurgery (SRS) to treat these tumors. This treatment can effectively control brain tumors while helping protect healthy brain tissue. However, when brain tumors or the areas where tumors were surgically removed are larger, treatment outcomes in terms of side effects and tumour control can become worse. Specifically, standard SRS on larger areas can have lower tumour control and higher risk of side effects, particularly a condition called radiation necrosis, which can cause swelling and damage in nearby healthy brain tissue.\n\nCurrently at Sunnybrook, large brain tumors are typically treated with SRS spread over 5 daily treatments using a machine called a linear accelerator. While this approach works well for many patients, it may be possible to improve results by combining two different types of radiation therapy machines - the linear accelerator and another specialized machine called the Gamma Knife.\n\nIn this study, the investigators want to test a new treatment approach where patients first receive 4 daily treatments using the linear accelerator, followed by a 1-2 week break, and then a final treatment using the Gamma Knife. The break between treatments allows the study doctors to take new scans and precisely target any remaining tumor, which may shrink during the break, thereby potentially reducing the amount of healthy brain tissue exposed to radiation. The Gamma Knife is also particularly good at delivering very precise radiation while sparing nearby healthy tissue. Lastly, there may be unique biological mechanisms between the two technologies that could be taken advantage of, by combining the technologies in the participant's treatment plan, to improve cancer control.\n\nThe investigators believe this combined approach might help achieve better tumor control while reducing the risk of side effects compared to using just the linear accelerator. This study will help the investigators understand if this new treatment strategy is safe and effective for patients with large brain tumors or surgical cavities, and whether it leads to better outcomes than the current treatment approach.",[28,187,188],"Brain Metastasases","SRS","2025-09-05",{"date":191,"type":48},"2025-09-09",{"date":193,"type":48},"2025-07-14",{"date":195,"type":20},"2030-06",{"name":197,"class":55},"Sunnybrook Health Sciences Centre",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":65,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":206,"conditions":207,"keywords":213,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":227,"locationsCount":56},"100602692","a-vision-language-foundation-model-for-brain-disease-diagnosis-from-multimodal-data-100602692","NCT07126821","A Vision-Language Foundation Model for Brain Disease Diagnosis From Multimodal Data","Inclusion Criteria:\n\nPatients with brain diseases:\n\n* Patients with brain tumors were pathologically diagnosed.\n* Patients with other brain diseases were correctly diagnosed.\n* The clinical case data of all patients were complete.\n\nNon-brain disease population:\n\n* All patients have complete clinical case data, complete brain MRI, no history brain diseases, no brain surgery or other brain diseases that affect the diagnosis and observation of MR imaging.\n\nExclusion Criteria:\n\n* Cases in which MRI were incomplete or with significant noise and artifacts.",{"count":205,"type":20},100000,"The goal of this observational study is to develop an innovative, comprehensive, and explainable AI vision-language foundation model (VLM) to advance the diagnosis and interpretation of brain diseases using multi-modal data. We will include patient demographics, medical imaging data (such as MRI, CT, and PET scans), histopathological data, genomic data when available, and other necessary laboratory examinations and tests to establish a screening and diagnostic model for brain diseases.",[28,208,209,210,211,212],"Brain Arterial Disease","Neuro-Degenerative Disease","Brain Tumors","Brain Diseases","Neurological di",[214,215,216,217,218,219,220],"brain tumors","brain cancers","brain diseases","foundation model","diagnosis","prediction","neurological diseases","2025-08-15",{"date":223,"type":48},"2025-08-17",{"date":225,"type":48},"2025-05-15",{"date":171,"type":20},{"name":228,"class":55},"Xiangya Hospital of Central South University",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":237,"targetDuration":239,"studyType":68,"phases":4,"briefSummary":240,"conditions":241,"keywords":243,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":4},"100595771","3d-decision-support-tool-for-brain-tumour-surgery-development-and-validation-observational-study-100595771","NCT07036783","3D Decision Support Tool for Brain Tumour Surgery Development and Validation: Observational Study","Multimodal Data Collection for the Development and Validation of the STRATUM Tool to Assist Surgery in Patients Affected by Brain Tumours: Observational Study","STRATUM-OS","Inclusion Criteria:\n\n* Adult patients (≥18 y\u002Fo).\n* Patients with planned surgery for suspected intraaxial malignant brain tumours (both primary and secondary) at any of the participating clinical institutions.\n\nExclusion Criteria:\n\n* Inability to deliver informed consent (unless provided by the tutor).\n* Participants in this study who have already undergone brain surgery during STRATUM-OS and need a revision surgery.",{"count":238,"type":20},320,"6 Months","This observational study (STRATUM-OS) aims to collect the necessary data from a cohort of patients with planned surgery for suspected intra-axial malignant brain tumours (both primary and secondary) following the standard surgical procedure established in current clinical protocols. These data will serve two primary purposes:\n\ni) To gather multimodal data (pre, intra and postoperative) essential for the development and technical validation of a 3D decision support tool for brain surgery guidance and diagnostics integrating augmented reality and multimodal data processing powered by artificial intelligence algorithms (called STRATUM tool);\n\nii) To collect outcome measures that will facilitate a subsequent comparative study (a non-randomized controlled clinical trial, called STRATUM-NRCCT) assessing the standard procedure alone versus the standard procedure augmented with the STRATUM tool. Patients from STRATUM-OS will act as a historical control group in the subsequent historically controlled clinical trial (STRATUM-NRCCT), which will be performed once STRATUM-OS has been completed.\n\nIn STRATUM-OS patients will receive standard care as per established clinical protocols, with no modification to their treatment. However, patients will be asked to grant access to their clinical information, complete questionnaires, and provide relevant pre, intra and postoperative information related to the surgical intervention. Data will be gathered from multiple sources, such as the Electronic Health Records (EHR), patient completed questionnaires, interviews, and reports from healthcare professionals involved in the surgical procedure. Additionally, intraoperative data will be collected from the different devices in the operating room.",[28,242],"Brain Tumor, Primary",[244,245,246,247],"Hyperspectral Imaging","Brain Tumour","Neurosurgery","Multimodal imaging","2025-06-17",{"date":250,"type":48},"2025-06-25",{"date":252,"type":20},"2025-07-01",{"date":254,"type":20},"2027-04-30",{"name":256,"class":55},"Fundación Canaria Instituto de Investigación Sanitaria de Canarias",{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":266,"conditions":267,"keywords":268,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":56},"100585219","project-milano-connections-between-patients-with-brain-tumors-and-their-pets-an-analysis-of-concerns-and-needs-100585219","NCT06899516","Project MILANO: Connections Between Patients With Brain Tumors and Their Pets: an Analysis of Concerns and Needs","MILANO","Inclusion Criteria:\n\n* Patients diagnosed with a brain tumor.\n* Patients who own at least one pet.\n\nExclusion Criteria:\n\n* Patients who decline to participate in the study.\n* Patients unable to complete the questionnaire.",{"count":265,"type":20},65,"Context and problem\n\nIn France, 61% of households own a pet, highlighting the significant role pets play in the daily lives. Patients diagnosed with brain tumors face specific challenges that may affect their ability to care their pets, including:\n\n* Progressive neurological deficits (cognitive and\u002For motor), limiting their autonomy,\n* A life-threatening prognosis.\n\nIn this context, the well-being of pets when their owner's health deteriorates becomes a critical concern. Indeed:\n\n* Social isolation and the progressive loss of physical and cognitive abilities complicate pet care, particularly during prolonged hospitalizations or in the event of death,\n* The lack of appropriate facilities and care solutions causes stress for pets, who are often unprepared for such transitions, and adds to the emotional burden on patients.\n\nWhy focus on patients with brain tumors?\n\n* These patients have specific needs due to the rapid progression of their condition,\n* A local study showed that 12% of patients with gliomas live alone, a significantly higher rate than in other cancer types. Patients who live alone are particularly exposed to issues related to their pet's future,\n* Given the high morbidity and mortality associated with brain tumors, proactive planning for pet care is particularly urgent.",[28],[269,270,271,272],"Brain tumors","Glioma patients","Pet care","Emotional burden","2025-04-01",{"date":275,"type":48},"2025-04-03",{"date":277,"type":48},"2025-03-20",{"date":279,"type":20},"2026-03",{"name":281,"class":55},"Centre Hospitalier Universitaire de Saint Etienne",{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":21,"phases":291,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":56},"100573154","phase-1-study-of-mt027-in-patients-with-brain-meninges-and-spinal-cord-metastatic-solid-tumors-100573154","NCT06742593","Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors","A Single-arm, Dose-escalating Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetic , and Efficacy of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors","Inclusion Criteria:\n\n1. Voluntarily participate in this study and provide a signed and dated written informed consent form prior to any study-specific procedures, sampling or analyses.\n2. Be aged 18 years or older, with no limitation on gender.\n3. Have a definite diagnosis of malignant tumor confirmed by pathology and\u002For histology (and provide complete pathological report information), and have been verified by biopsy, cytology, imaging examinations, etc. or have had previous confirmation of brain, meninges, spinal cord metastases, including lung cancer, breast cancer, colorectal cancer, melanoma, renal cell carcinoma, etc. Other solid tumor CNS metastases without standard treatment as judged by the investigator can also be considered for enrollment.\n4. The expected survival period is at least 3 months.\n5. The Karnofsky Performance Scale (KPS) score is ≥ 70 points. -\n\nExclusion Criteria:\n\n1. Known to be allergic to the investigational drug or its excipient components;\n2. Those with central nervous system metastases of hematological malignancies (such as lymphoma, leukemia, etc.);\n3. Those with metastases in the brainstem and high cervical spinal cord, including the midbrain, pons, medulla oblongata and C1\u002F2 cervical spinal cord segments;\n4. Those with severe insufficiency of heart, lung, liver and kidney functions; cardiac function: grade III or above according to the New York Heart Association (NYHA) criteria; liver function: grade C or above according to the Child-Pugh grading criteria; renal function: chronic kidney disease (CKD) stage 4 or above; renal insufficiency stage III or above; pulmonary function: severe respiratory failure symptoms involving other organs;\n5. Pregnant or lactating women;\n6. Those who are considered by the investigator to be unsuitable for participating in this clinical study due to any clinical or laboratory examination abnormalities or other reasons.",{"count":290,"type":20},12,[138],"MT027 is an off-the-shelf, allogeneic chimeric antigen receptor T cell (UCAR-T) injection prepared from healthy donor T cells targeting B7-H3. It is a next-generation, ready-to-use CAR-T product that can be used immediately and promptly for patients to solve the problem of unmet medical needs for a large number of patients who have a demand for CAR-T therapy but cannot receive it due to the common reasons of long production cycle, insufficient production capacity, and incompatibility of patients' T cells with the production conditions. In addition, the expected medical cost of allogeneic CAR-T cells is significantly lower, which can greatly alleviate the economic burden on patients.\n\nMT027 is prepared by expressing a chimeric antigen receptor (CAR) targeting B7H3 on gene-edited T cells through gene modification technology. MT027 products targeting the B7H3 target developed by Moxing Biotech avoid the potential graft-versus-host disease (GvHD) and host anti-graft reaction (HvGR) caused by the interaction between exogenous T cells and the patient's immune system, and have shown good safety and efficacy in recurrent high-grade glioma in the initial phase.",[28,294,210],"Brain and Central Nervous System Tumors","2024-12-17",{"date":297,"type":48},"2024-12-19",{"date":299,"type":20},"2025-01-01",{"date":301,"type":20},"2026-12-30",{"name":303,"class":304},"Suzhou Maximum Bio-tech Co., Ltd.","INDUSTRY"]